This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasm of vagina
C3_VAGINA
Vaginal neoplasm: Tumors or cancer of the VAGINA.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleonly females |
293218 |
2. Check conditionsNone |
293218 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
68 |
4. Check minimum number of eventsNone |
68 |
5. Include endpointsNone |
68 |
6. Filter based on genotype QC (FinnGen only) |
66 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of vagina
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of vagina, including Hilmo
- malignant neoplasm of female genital organs
- Solid cancers, helper endpoint
- Malignant neoplasm
- Malignant neoplasm, wide definition for exclusion
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 66 | 66 | - |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | - |
| Median age at first event (years) | 63.47 | 63.47 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 68
- Matched controls
- 680
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
128
Kela drug reimbursment
Cancers of female genital organs
+∞
44.8
38
*
C52.91
ICD-10 Finland
Squamous cell carcinoma of the vagina
+∞
43.5
37
*
8070/3-C52.9
ICD-O-3
Squamous cell carcinoma, NOS, of vagina, NOS
+∞
40.8
35
*
LEB00
NOMESCO Finland
Biopsy of vagina
167.0
38.9
38
5
A03FA01
ATC
metoclopramide; systemic, rectal
15.7
30.7
43
67
C52
ICD-10 Finland
Malignant neoplasm of vagina
+∞
26.8
24
*
ULA02
NOMESCO Finland
Kolposcopy
13.2
24.8
32
43
H02AB02
ATC
dexamethasone; systemic
72.7
24.6
27
6
WF002
NOMESCO Finland
Radical radiotherapy
170.0
23.2
23
*
C52.90
ICD-10 Finland
Malignant neoplasm of vagina without histologic examination
+∞
20.9
19
*
A04AA01
ATC
ondansetron; systemic, rectal
67.8
20.8
23
5
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
18.6
17
*
XLD00
NOMESCO Finland
Sytologyspecimen from mouth of uterus
9.6
18.3
29
49
N02AA05
ATC
oxycodone; systemic
9.3
18.2
30
53
C52.99
ICD-10 Finland
Malignant tumor of the vagina, unspecified histology
+∞
17.4
16
*
L03AA13
ATC
pegfilgrastim; parenteral
+∞
17.4
16
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
16.3
15
*
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
102.6
15.3
16
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
15.2
14
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
15.2
14
*
XX3DW
NOMESCO Finland
Time consuming IT work
22.7
14.6
21
13
JN2DG
NOMESCO Finland
Very extensive MRI examination of lower part of abdoment with high intensity magnet
94.4
14.2
15
*
A04AD12
ATC
aprepitant; systemic
+∞
14.0
13
*
ZX040
NOMESCO Finland
Intracavity HDR radiotherapy
+∞
14.0
13
*
WZC00
NOMESCO Finland
Treatment plan or consultation
6.7
14.0
41
126
UKC02
NOMESCO Finland
Cystoscopy
7.7
13.7
25
48
JN4BD
NOMESCO Finland
Extensive body CT
18.3
13.0
20
15
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
12.9
12
*
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
21.7
12.5
18
11
A04AA02
ATC
granisetron; systemic, transdermal
+∞
11.8
11
*
C52.92
ICD-10 Finland
Adenocarcinoma of the vagina
+∞
11.8
11
*
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
+∞
11.8
11
*
JN4AD
NOMESCO Finland
Body CT examination
14.1
11.2
19
18
LEC00
NOMESCO Finland
Partial excision of vagina
+∞
10.7
10
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
10.7
10
*
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
5.4
10.7
44
172
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
6.6
10.6
21
43
Z51.5
ICD-10 Finland
Palliative care
18.8
10.1
15
10
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
26.3
9.8
13
6
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
115.4
9.7
10
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
9.6
9
*
LFB00
NOMESCO Finland
Biopsy of vulva or perineum
13.4
8.8
15
14
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
102.2
8.6
9
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
8.5
8
*
130
Kela drug reimbursment
Malignant tumour
+∞
8.5
8
*
WC105
NOMESCO Finland
Simple cytostatic therapy of local tumor recidive
+∞
8.5
8
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
8.5
8
*
B01AB10
ATC
tinzaparin; parenteral
5.6
7.7
17
38
ZX090
NOMESCO Finland
Other technic of radiotherapy
89.4
7.6
8
*
A06AH03
ATC
naloxegol; oral
89.4
7.6
8
*
WW500
NOMESCO Finland
Blood transfusion
18.4
7.5
11
7
YL1CD
NOMESCO Finland
Very extensive CT examination of pelvis for dose design of radiotherapy
+∞
7.4
7
*
X77
ICPC
Malignant neopl genital female other
+∞
7.4
7
*
ZX095
NOMESCO Finland
Combined chemoradiotherapy
+∞
7.4
7
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
7.4
7
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
7.4
7
*
YX9VG
NOMESCO Finland
Other MRI eamination with high intensity magnet for dose design of radiotherapy
+∞
7.4
7
*
TKC20
NOMESCO Finland
Catheterisation of bladder
8.8
7.2
15
21
F43.29
ICD-10 Finland
Adaptation disorder UNS
44.6
6.9
8
*
D39.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other female genital organs
76.8
6.5
7
*
LEB10
NOMESCO Finland
Excision of lesion of vagina
29.7
6.4
8
*
J01EA01
ATC
trimethoprim; systemic
3.6
6.4
37
169
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
6.3
6
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
6.3
6
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
6.3
6
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
6.3
6
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
17.0
6.1
9
6
LAF10
NOMESCO Finland
Bilateral salpingo-oophorectomy
10.7
6.0
11
12
B01AB05
ATC
enoxaparin; parenteral
3.5
6.0
32
137
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
50
255
4.63
7.76
13.8
10.5
1.25
1.25
inr
0.00
11
72
51
291
4.01
6.14
23.4
6.1
3.57
4.13
e9/l
1.07
51
250
23
82
3.73
5.68
2.2
1.7
—
—
—
0
0
43
237
3.22
5.13
4.8
2.2
—
—
—
0
0
39
207
3.07
4.90
5.5
3.0
—
—
—
0
0
17
55
3.79
4.75
10.4
2.9
102.53
103.73
mmol/l
0.31
17
55
10
16
7.12
4.48
1.3
1.2
—
—
—
0
0
18
67
3.29
4.05
13.0
6.6
—
—
—
0
0
17
61
3.38
4.05
2.2
1.7
—
—
—
0
0
34
182
2.74
4.00
4.6
2.5
27.26
27.12
u/l
0.02
34
173
17
62
3.32
3.94
2.1
1.7
—
—
—
0
0
47
299
2.85
3.91
7.3
5.5
0.00
0.00
estimate
—
5
38
47
302
2.80
3.78
6.3
3.9
0.00
0.00
estimate
—
8
39
7
10
7.65
3.45
1.7
1.9
97.00
107.10
%
—
7
10
6
7
9.25
3.33
1.8
1.6
3.30
2.90
g/l
—
6
7
25
127
2.53
3.13
2.2
1.3
—
—
—
0
0
23
113
2.56
3.08
5.0
1.9
—
—
—
0
0
44
294
2.41
2.96
6.3
3.9
0.00
0.00
estimate
—
8
43
12
39
3.51
2.96
2.7
1.3
—
—
—
0
0
7
13
5.86
2.95
1.1
1.2
139.71
76.72
pmol/l
—
7
13
26
142
2.35
2.74
8.3
4.4
0.00
0.00
estimate
—
7
41
10
30
3.72
2.73
1.6
1.5
—
—
—
0
0
5
7
7.59
2.59
1.6
1.0
—
—
—
0
0
5
7
7.59
2.59
1.6
1.0
—
—
—
0
0
8
21
4.17
2.55
1.1
1.5
—
—
—
0
0
5
9
5.89
2.25
1.6
1.8
—
—
—
0
0
12
50
2.70
2.17
11.2
2.6
5.08
6.03
kpa
2.97
12
50
34
227
2.00
2.04
3.4
3.6
107.91
21.14
ng/l
0.46
26
165
5
11
4.81
1.97
1.4
1.2
—
—
—
0
0
40
287
1.96
1.91
10.1
4.2
1.20
1.23
mmol/l
1.24
34
260
53
605
0.44
1.87
5.1
4.9
5.87
5.94
mmol/l
0.28
47
562
5
12
4.40
1.85
1.4
2.8
—
—
—
0
0
10
43
2.55
1.67
4.1
3.5
1.28
1.29
mmol/l
—
10
43
8
32
2.69
1.66
5.9
2.1
24.07
26.16
mmol/l
—
8
32
32
227
1.77
1.48
7.5
3.9
—
—
—
0
0
5
18
2.91
1.31
2.2
1.8
—
—
—
0
0
5
19
2.76
1.24
1.2
1.8
—
—
—
0
0
7
30
2.48
1.16
2.6
1.4
—
—
—
0
0
7
31
2.40
1.14
5.0
2.9
0.74
0.69
%
—
7
31
7
31
2.40
1.14
5.0
2.9
1.56
1.34
%
—
7
31
10
52
2.08
1.13
12.8
2.4
1.08
0.99
mmol/l
—
10
45
5
22
2.37
1.05
17.4
3.0
22.30
25.40
mmol/l
—
5
22
18
120
1.68
0.98
1.3
1.9
403.44
483.59
pmol/l
0.88
18
99
10
56
1.92
0.93
2.3
3.5
425.20
155.31
ng/l
—
10
51
62
651
0.46
0.92
49.3
17.6
121.31
132.80
g/l
6.80
62
636
6
29
2.17
0.92
6.3
2.8
49.07
46.31
%
—
6
29
8
47
1.79
0.84
3.1
3.4
—
—
—
0
0
5
29
1.78
0.65
7.0
2.1
1.06
1.26
%
—
5
29
30
249
1.37
0.56
4.0
2.6
240.10
76.80
ug/l
1.67
25
225
5
32
1.61
0.43
1.4
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
61
582
1.47
0.33
29.4
11.9
31.85
20.04
mg/l
1.95
55
417
47
500
0.81
0.28
38.0
14.1
16.06
15.29
%
0.35
47
491
37
340
1.19
0.24
2.9
2.7
—
—
—
0
0
16
136
1.23
0.23
2.9
2.0
433.56
8339.03
umol/l
1.05
16
117
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
61
618
0.87
0.18
34.4
14.0
138.43
139.91
mmol/l
2.92
61
600
15
134
1.15
0.12
1.1
1.3
0.55
1.64
u/ml
—
6
31
23
214
1.11
0.10
2.9
3.6
8.57
3.40
mg/mmol
0.68
16
131
61
617
0.89
0.08
34.3
14.2
4.01
3.95
mmol/l
0.85
61
599
9
104
0.85
0.07
1.0
1.5
—
—
—
0
0
28
270
1.06
0.04
1.7
2.1
79.34
102.48
pmol/l
2.78
14
115
55
557
0.93
0.02
21.0
10.9
70.84
76.48
ml/min/173m2
1.01
49
441
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
10.62
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
4.71
—
0
7
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
62
618
1.04
-0.00
33.5
13.7
82.08
69.87
umol/l
0.73
62
618
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_VAGINA – Malignant neoplasm of vagina
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).